Matching articles for "ProCentra"
Issue 1736 · September 1, 2025
Drugs for ADHD

Attention-deficit/hyperactivity disorder (ADHD) is a common chronic neurodevelopmental disorder often diagnosed in school-age children that frequently persists into adulthood.Pharmacologic treatment of ADHD…

Med Lett Drugs Ther. 2025 Sep 1; 67(1736):137-44 doi:10.58347/tml.2025.1736a
Attention-deficit/hyperactivity disorder (ADHD) is a common chronic neurodevelopmental disorder often diagnosed in school-age children that frequently persists into adulthood.Pharmacologic treatment of ADHD has been associated with reduced risks of substance abuse, criminal behavior, unintentional injuries, serious traffic accidents, and all-cause mortality. Drugs approved by the FDA for treatment of ADHD are listed in Table 1.
Issue 1664 · November 28, 2022 Free
In Brief: Alternatives to Adderall

The short-acting formulation of mixed amphetamine salts ( Adderall , and generics) FDA-approved for treatment of attention-deficit hyperactivity disorder (ADHD) and narcolepsy, is currently in short supply in…

Med Lett Drugs Ther. 2022 Nov 28; 64(1664):191-2
The short-acting formulation of mixed amphetamine salts ( Adderall , and generics) FDA-approved for treatment of attention-deficit hyperactivity disorder (ADHD) and narcolepsy, is currently in short supply in the US. Until an adequate supply is restored, patients may be looking for alternatives.
Issue 1590 · January 27, 2020
Drugs for ADHD

Attention-deficit/hyperactivity disorder (ADHD) is a chronic neurodevelopmental disorder that has been diagnosed in up to 10% of school-age children in the US and frequently persists into adulthood. A study in…

Med Lett Drugs Ther. 2020 Jan 27; 62(1590):9-15
Attention-deficit/hyperactivity disorder (ADHD) is a chronic neurodevelopmental disorder that has been diagnosed in up to 10% of school-age children in the US and frequently persists into adulthood. A study in a large Danish cohort found that ADHD was associated with higher mortality rates in children, adolescents, and adults, mainly due to accidents. Pharmacologic treatment of ADHD in children has been reported to decrease the risk of substance abuse in adolescents, and use of ADHD medications in adults has been associated with a reduced risk of serious traffic accidents and criminal behavior.4-6 Drugs approved by the FDA for treatment of ADHD are listed in Table 1.
Issue 1549 · June 18, 2018
A New Amphetamine Oral Suspension (Adzenys ER) for ADHD (online only)

The FDA has approved an extended-release oral suspension formulation of amphetamine ( Adzenys ER – Neos) for treatment of attention deficit hyperactivity disorder (ADHD) in patients ≥6 years old. The same…

Med Lett Drugs Ther. 2018 Jun 18; 60(1549):e106-8
The FDA has approved an extended-release oral suspension formulation of amphetamine ( Adzenys ER – Neos) for treatment of attention deficit hyperactivity disorder (ADHD) in patients ≥6 years old. The same extended-release amphetamine product is available as an orally disintegrating tablet and is marketed as Adzenys XR-ODT . Another extended-release oral suspension formulation of amphetamine, Dyanavel XR , was approved earlier.